Adasuve ( Alexza/Ferrer) is EU approved to control agitation in Schizophrenia patients
Alexza Pharmaceuticals, Inc.and Grupo Ferrer Internacional, S.A.,announced that the European Commission has granted marketing authorization for Adasuve (Staccato loxapine). In the European Union (EU), Adasuve 4.5 mg and 9.1 mg inhalation powder loxapine, pre-dispensed, is authorized for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder
The Adasuve marketing authorization requires that patients receive regular treatment immediately after control of acute agitation symptoms, and that Adasuve is administered only in a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should be available for treatment of possible severe respiratory side-effects (bronchospasm).
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins